Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, Texas.
Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, Texas; Weill Medical College of Cornell University, New York, New York.
J Am Soc Cytopathol. 2024 May-Jun;13(3):227-232. doi: 10.1016/j.jasc.2024.01.004. Epub 2024 Jan 29.
Atypical glandular cells (AGC) represent less than 1% of Pap test cases and include a variety of lesions in both the cervix and endometrium. The study aimed to investigate the cytology-histology correlation in AGC patients and to evaluate the clinical utility of hrHPV testing in this diagnostic context.
We identified 491 atypical glandular cells (AGC) cases in our quality analysis (QA) database of 336,064 Pap tests interpreted between March 1, 2013 and July 12, 2016. Of these, 251 cases had follow-up biopsies with hrHPV tests in 148 cases.
The most common histologic diagnosis associated with AGC was normal/benign or low-grade lesions, comprising 55% of cervical biopsies and 24% of endometrial biopsies. High-grade lesions were identified in 21% of follow-up biopsies. In patients with AGC cytology, a positive hrHPV test significantly increased the likelihood of cervical HSIL or above lesions on biopsy by 26.4 times (OR = 26.4, 95% CI: 5.8-119.4, P < 0.0001). A positive genotyping result for HPV 16 dramatically increased the likelihood of cervical HSIL or above lesions on biopsy (OR = 84, 95% CI: 12.0-590.5, P < 0.0001). The HPV test had a negative predictive value of 97% (CI: 85%-100%).
Our study confirms that AGC is a significant diagnosis with an overall risk for high-grade cervical or endometrial lesions as high as 21%. hrHPV testing with genotyping is an effective tool for identifying high-risk individuals within the AGC population, with excellent positive and negative predictive values. This approach is valuable for clinical risk stratification and differential diagnosis in patients with AGC cytology.
非典型腺细胞(AGC)占巴氏涂片检查病例的不到 1%,包括宫颈和子宫内膜的各种病变。本研究旨在探讨 AGC 患者的细胞学-组织学相关性,并评估 hrHPV 检测在这种诊断背景下的临床应用价值。
我们在 2013 年 3 月 1 日至 2016 年 7 月 12 日期间对 336064 例巴氏涂片检查的质量分析(QA)数据库中确定了 491 例非典型腺细胞(AGC)病例。其中,251 例有随访活检,148 例进行了 hrHPV 检测。
与 AGC 最常见的组织学诊断是正常/良性或低级别病变,占宫颈活检的 55%,子宫内膜活检的 24%。在随访活检中发现 21%为高级别病变。在 AGC 细胞学患者中,hrHPV 检测阳性显著增加了活检时宫颈 HSIL 或以上病变的可能性,增加了 26.4 倍(OR=26.4,95%CI:5.8-119.4,P<0.0001)。HPV 16 的阳性基因分型结果显著增加了活检时宫颈 HSIL 或以上病变的可能性(OR=84,95%CI:12.0-590.5,P<0.0001)。HPV 检测的阴性预测值为 97%(CI:85%-100%)。
本研究证实,AGC 是一种具有重要意义的诊断,其总体风险高达 21%,存在高级别宫颈或子宫内膜病变的风险。hrHPV 检测联合基因分型是识别 AGC 人群中高危个体的有效工具,具有极好的阳性和阴性预测值。这种方法对于 AGC 细胞学患者的临床风险分层和鉴别诊断具有重要价值。